Replies to post #23446 on RespireRx Pharmaceuticals Inc (RSPI)

[Aiming4]

haysaw - Neuro's answer will of course be the factual and meaningful one, but I'll take a shot at it for fun:

1. Even the vet medicine angle requires Cortex to prove their proposed drug is safe and has some efficacy. The size of that market along with Cortex's bank account balance doesn't dictate putting resources into that right now. I think the FDA oversees Vet drugs as well.

2. First I don't think Cortex could get much upfront for the HIs right now... if anyone wanted to license them at this point, I'd think they'd just be better off buying the company. And from Cortex's perspective, the HIs are Cortex's best bet at hitting a grand slam in the future... it's looking more and more like Cortex will have to license the LIs under duress and once again for lowball numbers. If Cortex gives away the farm by licensing HIs at this early point, it's hard to see where Cortex will ever have a chance at a spectacular price gain in the future.

[neuroinv]

No, actually I was responding to Iggs' snarky reply that <<the strategy has changed with the wind for years>>. As if this was all based on whim, rather than dictated by fiscal reality. I didn't have any issue with your being curious....

So far as a HI deal is concerned, I believe Aiming is correct when he says that they wouldn't get anything worthwhile. Big Pharmas are focused on programs where they can see commercial potential in the near future, relatively speaking. The HI's havent shown that yet.

At the moment, LI's in SA and ADHD are of more value at the moment, and RD as well, since they have POC, even though it's a smaller market compared to those two.

Vet medicine would have seemed a painless way to get some cash, so the fact that we have heard nothing more makes me believe that Jim Coleman didnt have any luck raising partner interest, and instead moved on to bigger things (RD/SA/ADHD).

Personally, I don't expect to hear anything new at Roth, though I'd be happy to be surprised. If there was something material to report, and that's the only kind of news I care about, ordinarily they'd have to send out a press release beforehand. Now, with the market closed, perhaps that changes things. But Roth is a relatively local event,mainly Southern CA companies (it's all of 45 minutes north of here, and it's never been worth my time to go). it's not something with a high profile where one would aim a major announcement.

And nothing satisfying can be said until it is material and must be said, because until that point, it is confidential and still in process.

NeuroInvestment